901P Matching-adjusted indirect comparisons (MAIC) of safety between single-agent belantamab mafodotin versus selinexor plus dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Abstract

Background: Plasmablastic lymphoma (PBL) is a rare, aggressive subtype of non-Hodgkin's lymphoma. Effective treatment options are lacking due to the rarity of the disease.Methods: We conducted a systematic review of the PubMed and our internal records to retrieve cases with PBL diagnosis with evaluable treatment outcomes. Aggressive chemotherapy was defined as more intense regimens than CHOP.